Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma

NCT07809100 · tracked via the Priya Life Science France tracker

Sponsor

Centre Hospitalier Sud Francilien

Phase

Not applicable

Started

2026-10-01

Last updated

2026-09-09

Condition(s) studied

Squamous Cell Cancer of Head and Neck (SCCHN)

Investigational drug(s) / intervention(s)

Tissue and secretion sampling via biopsyTissue and secretion sampling via biopsy

Tissue and secretion sampling via biopsy: Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect: * Tumor tissue * Adjacent healthy mucosa * Pharyngeal secretions These samples are used for microbiome analysis. head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention.

Study summary

Head and neck squamous cell carcinoma (HNSCC), France's 5th most common cancer (15,000 annual cases), presents significant public health challenges due to high morbidity and functional/aesthetic sequelae from treatments (mutilating surgery, radiotherapy, chemotherapy). Major risk factors, tobacco and alcohol, create a chronic inflammatory environment promoting tumor development. The upper aerodigestive tract microbiome, influenced by these exposures and local alterations (necrosis, bleeding, ulcerations), is emerging as a potential factor in tumor progression, severity biomarker, or therapeutic target, though its exact role (cause or consequence) remains to be elucidated

Objectives:

* Primary: Compare bacterial microbiome composition between tumor tissue, adjacent healthy mucosa, and pharyngeal secretions
* Secondary:
* Correlate microbiome diversity/composition with clinical and epidemiological characteristics
* Identify microbiome variations by tumor stage, histology, and infiltration
* Discover diagnostic/prognostic microbial markers
* Analyze somatic variants (SNP/CNV) via whole-genome sequencing (WGS) and their association with microbiome profiles and clinical parameters

Study Design: Prospective, cross-sectional study with paired design (each patient serves as their own control to minimize genetic variation biases)

Methods:

* Samples: Tumor, adjacent healthy tissue, and pharyngeal secretions (3 samples/patient)
* Sequencing: Metagenomic sequencing (complete bacterial genomes) when biomass permits, or targeted 16S rRNA sequencing to identify dominant genera.
* Pilot study: 20 patients to select the optimal technique and validate feasibility, particularly assessing DNA quantity in these low-biomass environments

Population: Adults with suspected HNSCC scheduled for panendoscopy

Exclusion criteria: Recent antibiotics/corticosteroids (12 weeks), immunosuppression (uncontrolled HIV, active hematologic malignancies, autoimmune diseases on immunosuppressants, organ/stem cell transplants, uncontrolled diabetes), immunomodulatory treatments (3 months), recurrence, pregnancy, non-French speakers, legal guardianship, or lack of social security.

Safety: No additional risks beyond standard panendoscopy.

Expected impact: This approach may pave the way for innovative diagnostic or therapeutic strategies based on microbiome modulation in HNSCC.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult patient * Consultation in the ENT department for suspected squamous cell carcinoma of the upper aerodigestive tract scheduled for panendoscopy * Patient has provided consent to participate in the study and signed an informed consent form Exclusion Criteria: * Antibiotic or corticosteroid therapy within 12 weeks prior to consultation * Conditions associated with immunosuppression: * Uncontrolled HIV infection (CD4 \< 200 cells/µL) (permanent exclusion) * Hematologic malignancies currently under treatment or not in complete remission for \<2 years * Autoimmune diseases under immunosuppressive treatment * Solid organ or stem cell transplant recipients (permanent exclusion) * Poorly controlled diabetes (HbA1c \> 9%) * Immunomodulatory treatment within 3 months prior to consultation: * Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4) * Biotherapy targeting the immune system (anti-TNF, anti-IL, calcineurin inhibitors, antimetabolites) * Recurrent upper aerodigestive tract cancer previously treated with surgery and/or radiochemotherapy * Pregnancy (confirmed prior to panendoscopy) * Patient who does not speak or understand French * Subject under guardianship or curatorship * Subject not affiliated with the national health insurance system

Primary outcome measure(s)

The difference in bacterial composition between the tumor, healthy mucosa, and hypopharyngeal secretions will be assessed — at day 1

Trial sites (1)

Facility	City	Region	Status
Centre Hospitalier Sud Francilien	Corbeil-Essonnes	France

More Centre Hospitalier Sud Francilien trials in France

Study of Ventilator Associated Event During Intensive Care After Resuscitated Cardiac Arrest. Recruiting

Study of Pre Hospital Management of Polytrauma Patients by Medical Teams From a Department in the Parisian Region Starting soon

Barriers and Facilitators to Psychosocial Management in Cardiac Rehabilitation at the South Francilien Hospital Center (CHSF) Starting soon

Evaluation of the Benefit of Exercise Testing for the Diagnosis of Obstruction in the Coronary Arteries of the Heart Recruiting

Reactions to Oro-facial Solicitations : a Predictor of Eating Difficulties for Premature Babies of 36 Weeks Gestation Adjusted Age Starting soon

Other trials for the same condition

Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07809100 on ClinicalTrials.gov ↗ ← All trials in France